Family-wide analysis of human macrodomains reveals novel activities and identifies PARG as most efficient ADPr-RNA hydrolase
ADP-ribosylation is well-known as protein posttranslational modification and was recently also identified as RNA posttranscriptional modification. When macrodomain proteins were identified as protein ADP-ribosylhydrolases, several ADP-ribosylation substrates were not yet identified. Therefore, the majority of macrodomain-containing proteins have not been tested towards these additional substrates and were considered to be inactive. Here, we compare in vitro activities of the human macrodomains on a range of ADP-ribosylated substrates. We confirm recent findings that PARP9macro1 and PARP14macro1 can remove ADP-ribose from acidic residues and provide evidence that also PARP14macro2 and PARP15macro2 can function as ADP-ribosylhydrolases. In addition, we find that both PARP9macro1 and PARP14macro1 are active as ADPr-RNA decapping protein domains. Notwithstanding these in vitro activities, our data furthermore indicate that in HEK293 cells, PARG is the major ADPr-RNA decapping enzyme. Our findings thus expand the spectrum of known catalytic activities of human macrodomains and demonstrate their different efficiencies towards nucleic acid substrates.
Authors
- Karla L. H. Feijs (ORCID: https://orcid.org/0000-0002-8074-2180)
- Gülcan Aydın (ORCID: https://orcid.org/0000-0003-3140-7818)
- Bernhard Lüscher (ORCID: https://orcid.org/0000-0002-9622-8709)
- Nonso Josephat Ikenga (ORCID: https://orcid.org/0000-0002-2206-7121)
- Lisa Weixler (ORCID: https://orcid.org/0000-0003-4453-017X)
- Roko Žaja (ORCID: https://orcid.org/0000-0003-3944-0153)
- Sven Wijngaarden (ORCID: https://orcid.org/0000-0002-6449-4113)
- Dmitri V. Filippov (ORCID: https://orcid.org/0000-0002-6978-7425)
- Ganga Mohan
- Jonas Siefert
Institutions
- Leiden University (NL)
- University Hospital Bonn (DE)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Communications Biology
- Published
- 2025-03-18
- DOI
- https://doi.org/10.1038/s42003-025-07901-7
- Citations
- 5
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 5.23
Funders
- Ribon Therapeutics
- Deutsche Forschungsgemeinschaft
- RWTH Aachen University
- Medizinische Fakultät, RWTH Aachen University